Thymoma
58
9
15
22
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
11 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.3%
6 terminated out of 58 trials
78.6%
-7.9% vs benchmark
3%
2 trials in Phase 3/4
50%
11 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (58)
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Molecular Analysis of Thoracic Malignancies
SP Thoracic IDE Study
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Clinical Investigation of the da Vinci Surgical System
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)